Improved IR780 derivatives bearing morpholine group as tumor-targeted therapeutic agent for near-infrared fluorescence imaging and photodynamic therapy
Source abstract
Abstract
Abstract To improve of the potency of IR780 in this field of anticancer research, we designed and synthesized two novel IR780-based derivatives (L1 and L2) possessing different chainlength tethered morpholine groups. Their properties were verified through both in vitro and in vivo experiments, including good photo- and chemical stability, dual tumor-targeted property, and near-infrared fluorescence imaging and targeted PDT. Meanwhile, L1 was further verified for potential practicability, including the hypotoxicity and the mixed route of elimination from the body, through the in vivo experiment. All results show that that our tactics provide a protocol for improvement of the potency of IR780 in the field of anticancer research.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Click Chemistry and Applications · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Innovative strategies for hypoxic-tumor photodynamic therapy10.1002/ange.201805138 ↗
2. In vivo albumin traps photosensitizer monomers from self-assembled phthalocyanine nanovesicles: a facile and switchable theranostic approach10.1021/jacs.8b12167 ↗
3. A semiconducting polymer nano-prodrug for hypoxia-activated photodynamic cancer therapy10.1002/anie.201814730 ↗
4. Activatable near-infrared emission-guided on-demand administration of photodynamic anticancer therapy with a theranostic nanoprobe10.1039/C8SC04854A ↗
5. Upconversion-mediated ZnFe2O4 nanoplatform for NIR-enhanced chemodynamic and photodynamic therap10.1039/C9SC00387H ↗
6. Benzo[a]phenoselenazine-based NIR photosensitizer for tumor-targeting photodynamic therapy via lysosomal-disruption pathway10.1016/j.dyepig.2019.107617 ↗
7. Biomarker displacement activation:a general host–guest strategy for targeted photo -theranostics in vivo10.1021/jacs.8b02331 ↗
8. Superoxide radical photogenerator with amplification effect:surmounting the achilles' heels of photodynamic oncotherapy10.1021/jacs.8b13141 ↗
9. Development of a red absorbing Se-rhodamine photosensitizer and its application for bio-orthogonally activatable photodynamic therapy10.1039/C9CC03018B ↗
10. Organic photodynamic nanoinhibitor for synergistic cancer therapy10.1002/anie.201903968 ↗
11. Targeting photodynamic and photothermal therapyto the endoplasmic reticulum enhances immunogenic cancer cell death10.1038/s41467-019-11269-8 ↗
12. A novel tumor and mitochondria dual-targeted photosensitizer showing ultra-efficient photodynamic anticancer activities10.1039/C8CC09456J ↗
13. Supramolecular photosensitizers rejuvenate photodynamic therapy10.1039/C7CS00594F ↗
14. In vivo imaging of endogenously produced HClO in zebrafish and mice using a bright, photostable ratiometric fluorescent probe10.1021/acs.analchem.9b00224 ↗
15. Automated stoichiometry analysis of single-molecule fluorescence imaging traces via deep learning10.1021/jacs.9b00688 ↗
16. Low. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer10.1021/acs.jmedchem.8b01115 ↗
17. A thermoresponsive nanocarrier for mitochondria-targeted drug delivery10.1039/C9CC00603F ↗
18. Mitochondria -targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications10.1021/acs.chemrev.7b00042 ↗
19. Mitochondria- and lysosomes -targeted synergistic chemo-photodynamic therapy associated with self-monitoring by dual light-up fluorescence10.1002/adfm.201804362 ↗
20. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase10.1016/j.ccr.2013.08.003 ↗
21. Recent advances in near-infrared II fluorophores for multifunctional biomedical imaging10.1039/C8SC01153B ↗
22. Approach to a substituted heptamethine cyanine chain by the ring opening of zincke salts10.1021/jacs.9b02537 ↗
23. Facile supramolecular approach to nucleic-acid-driven activatable nanotheranostics that overcome drawbacks of photodynamic therapy10.1021/acsnano.7b07809 ↗
24. Sequential protein-responsive nanophotosensitizer complex for enhancing tumor-specific therapy10.1021/acsnano.9b01100 ↗
25. Synthesis and photophysical properties of meso-aminophenyl-substituted heptamethine dyes as potential leads to new contrast agents
26. Mitochondria-targeting IR-780 dye and its derivatives: synthesis, mechanisms of action, and theranostic applications10.1002/adtp.201800069 ↗
27. Methionine-decorated near infrared fluorescent probe for prolonged tumor imaging10.1021/acs.molpharmaceut.8b00233 ↗
28. A near-infrared heptamethine aminocyanine dye with a long-lived excited triplet state for photodynamic therapy10.1039/C8CC04582H ↗
29. Tumor-targeted small molecule for dual-modal imaging-guided phototherapy upon near-infrared excitation10.1039/C7TB02496G ↗
30. Phthalocyanine derivatives possessing 2-(morpholin-4-yl)ethoxy groups as potential agents for photodynamic therapy10.1021/acs.jmedchem.5b00052 ↗
31. A rhodamine-based single-molecular theranostic agent for multiplefunctionality tumor therapy10.1016/j.dyepig.2019.03.009 ↗
32. Single chemosensor for double analytes: spectrophotometric sensing of Cu2+ and fluorogenic sensing of Al3+ under aqueous conditions10.1007/s10895-015-1710-2 ↗
33. Glucose oxidase and polydopamine functionalized iron oxide nanoparticles: combination of photothermal effect and reactive oxygen species generation for dual-modality selective cancer therapy10.1039/C8TB03320J ↗